Drug Database
CO

COVID-19 vaccine (Abdala / CIGB 66 / CIGB66)

✓ Approved

CIGB · Vaccine · Vaccine

What is COVID-19 vaccine?

COVID-19 vaccine is a vaccine developed by CIGB. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesAbdala, CIGB 66, CIGB66
CompanyCIGB
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, CIGB

Therapeutic Indications

COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsCOVID-19✓ Approved

Related Research Articles

PubMedIranian journal of nursing and midwifery research2026-07-17

Investigate the Relationship Between Receiving the COVID-19 Vaccine and Menstrual Disorders among Females of Reproductive Age in Jeddah, Saudi Arabia.

Esheaba Ola M OM, Fouly Howieda A HA, Kassem Fathia K FK

There are many physical side effects of the COVID-19 vaccine, including unexpected changes occurring in menstrual bleeding. This study aimed to assess the relation between the COVID-19 vaccine and disorders in menstruation among females of reproductive age. Participants were recruited from a nonprobability snowball sampling targeted at females who are living in Jeddah city between March 2022 and August 2022, Kingdom of Saudi Arabia (KSA). A quantitative cross-sectional design was utilized to conduct the study, a nonexperimental design based on a single observation point. The sample size is estimated by the G*Power software to be 180, considering missed cases, it increased to 197. Regarding menstrual changes, n = 86 (43.65%) experienced a delay, and about one-third reported an earlier menstruation cycle. A significant relationship is observed between nationality, occupation, and changes in period (t = 3.89, P < 0.001 and t = -2.94, P < 0.004). There is no significant difference in the occurrence of complications among the different vaccine types. Receiving the COVID-19 vaccine was strongly linked with unexpected disturbance in menstruation among the studied group, from simple menstrual irregulates to reported amenorrhea after receiving the booster doses. However, the occurrence of menstrual cycle delays was not linked to the vaccine type. Further studies should be done to investigate each type of vaccine specifically to determine if the type of vaccine affects the reproductive function generally not only the menstrual cycle, in a larger survey for more generalizability.

PMID 42466287
Read full article →
PubMedmedRxiv : the preprint server for health sciences2026-07-17

COVID-19 mRNA Vaccination Reduces Guillain-Barré Syndrome Risk: Evidence from a Large Longitudinal Cohort Study.

Li Jinju J, Pan Yuanyi Y, Han Yun Y, Zhou Chuan C et al.

The association between COVID-19 vaccination and Guillain-Barré syndrome (GBS) has been previously investigated with inconsistent results, largely due to limited data and lack of concurrent controls. To address this problem, a large longitudinal cohort study was conducted using National COVID Cohort Collaborative (N3C) data. While COVID-19 infection was associated with increased GBS occurrence, COVID-19 vaccination was associated with significantly reduced GBS risk relative to unexposed (unvaccinated and uninfected) control, corresponding to a 61% lower 30-day risk (incidence risk ratio: IRR = 0.39, P < 0.01), consistent with multivariable Cox regression showing a similar reduction (adjusted hazard ratio: aHR = 0.41, P < 0.01). This protective association was observed only among recipients of mRNA vaccines (BNT162b2: IRR = 0.38, P < 0.01; mRNA-1273: IRR = 0.24, P < 0.01), but not among recipients of adenoviral-vector vaccines (IRR = 1.38, P > 0.05). Prior COVID-19 vaccination also reduced infection-associated GBS risk. Additional factors associated with GBS risk included sex, vaccine dose, and pre-existing comorbidities such as stroke, neurological disorders, and autoimmune diseases. Overall, our N3C large-scale study provides evidence that COVID-19 mRNA vaccination reduces GBS risk, supporting the safety profile of mRNA vaccines and warranting further mechanistic investigation.

PMID 42465888
Read full article →
PubMedJournal of translational medicine2026-07-17

Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.

Han Xu X, Jiang Hudachuan H, Zheng Hui H, Jin Pengfei P et al.

Compared with homologous boosting, heterologous boosting with a different COVID-19 vaccine following priming generates stronger antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as variants, particularly for inactivated COVID-19 vaccine(CoronaVac). However, it is still unclear about the potential immune enhancement mechanism underlying heterologous boosting. In this study, we isolated spike protein binding-specific monoclonal antibodies at day 180 post a homologous booster with CoronaVac or a heterologous booster with Ad5-nCoV based on two-dose of CoronaVac using the single B cell sorting platform. Subsequently, we verified their neutralization activity to SARS-CoV-2 variants, germline gene sequences and affinity kinetics targeting SARS-CoV-2 NTD/RBD/S1. Additionally, we conducted an in-depth analysis of the immunological response characteristics, by integrating single-cell RNA/V(D)J sequencing(scRNA/ V(D)J-seq). Our study demonstrated that heterologous boosting with Ad5-nCoV elicited more mature B cells with higher affinity and activated more abundant immune-related pathways compared to the homologous boosting with CoronaVac. In addition, Ad5-nCoV boosting expanded unique clonal types of B and T cells, whereas CoronaVac boosting led to a small-sized clonal expansion. Furthermore, the utilization of germlines associated with neutralizing antibody were preferentially enriched in recipients with Ad5-nCoV boosting. Above all, our study gives insights for elaborating the systemic immune landscape of heterologous-boosting COVID-19 immunization by the novel single B cell sorting platform and scRNA/V(D)J-seq technology. NCT04892459.

PMID 42464341
Read full article →
PubMedbioRxiv : the preprint server for biology2026-07-17

Molecular-level analysis of serum IgG repertoires in COVID-19-vaccinated people with cystic fibrosis identifies abundant convergent antibodies.

Ionov Steven S, Connor Ruth I RI, Curtis Nicholas C NC, Shin Seungmin S et al.

People with cystic fibrosis (pwCF) are at increased risk of severe disease following respiratory viral infections including influenza and respiratory syncytial virus, and were therefore given priority for COVID-19 vaccination. Retrospective epidemiological data have revealed a lower incidence of SARS-CoV-2 infection and a reduced fatality rate among pwCF than in the general population, possibly from the stringent infection control measures and early adoption of protective behaviors. Despite several reports of adequate binding and neutralizing titers after vaccination, the molecular features of vaccine-elicited serum antibody repertoires in pwCF remain unknown. We performed high-resolution proteomic analysis of serum IgG, combined with next-generation sequencing of B cells, to quantitatively profile Spike (S)-reactive serological repertoires from nine infection-naïve pwCF after two doses of COVID-19 mRNA vaccine. We recombinantly expressed 20 IgG clonotypes from 6 pwCF as monoclonal antibodies (mAbs) and measured their binding and neutralization against vaccine-strain and variant viruses. All donors mounted strong binding and neutralizing titers to vaccine-strain virus. Ig-Seq revealed diverse serum repertoires in all vaccinees, with antibodies targeting the receptor-binding domain (RBD) comprising 64% of each circulating repertoire by abundance. Several serum IgG clonotypes identified across our cohort shared identical or similar IGHV and CDRH3 amino acid sequences with serum IgG from other pwCF or S-reactive mAbs isolated from non-CF individuals. These 'convergent' antibodies made up 14.6% of the anti-S repertoires in our cohort, reaching 24.8% in one pwCF. Convergent antibodies tended to be RBD-reactive and enriched in specific IGHV ; surprisingly, a higher abundance of convergent antibodies in serum correlated with a lower breadth of serum neutralization. All 20 mAbs bound Wuhan S with high affinity (EC 50 < 10 nM), and only RBD-reactive mAbs conferred neutralization to vaccine or variant pseudovirus. While most mAbs bound both the B.1.617.2 (Delta, 17/20) and B.1.1.529 (Omicron, 12/20) strains, convergent mAbs were less likely to bind either variant. Post-vaccine serum IgG repertoires in pwCF are dominated by RBD-focused, high-affinity antibodies and include a substantial convergent component shared with non-CF vaccinees. These findings demonstrate that pwCF mount antibody responses comparable to the general population, and a large group of convergent antibodies may contribute to strain-specific rather than cross-variant immunity.

PMID 42465256
Read full article →
PubMedGlobalization and health2026-07-17

Institutional quality and pandemic resilience: cross-country evidence on health and economic outcomes during COVID-19.

Diaz Diego A DA, Larroulet Cristian C, Marticorena Andres A

The COVID-19 pandemic exposed large cross-country differences in mortality, vaccination rollout, and economic recovery. We examine whether stronger pre-pandemic institutions were associated with better pandemic performance and whether vaccination rollout helps explain part of that relationship. We combine 2019 World Bank Worldwide Governance Indicators with COVID-19 outcomes, policy measures, World Development Indicators, and V-Dem electoral democracy data, estimating cross-country regressions and a temporally ordered exploratory mediation model using vaccination by September 2021 and deaths accrued in the fourth quarter of 2021. In full multivariable specifications, a one-unit increase in the WGI composite is associated with 384 fewer reported COVID-19 deaths per million, 1,860 fewer excess deaths per million, and 15.5% points higher full vaccination coverage by end-2021. These associations remain in robustness checks using V-Dem electoral democracy controls, WGI principal-component measures, timing-specific outcomes, and influence diagnostics. Institutional quality is not robustly associated with GDP growth in 2020; its positive association with GDP growth in 2021 persists but is weaker after controlling for OxCGRT economic-support policies. The exploratory mediation decomposition is consistent with an indirect path through vaccination representing about 35% of the total association between institutional quality and late-2021 mortality. Pre-pandemic institutional quality was consistently associated with pandemic health outcomes and vaccine deployment, while economic associations were more phase-specific. The findings are observational and should not be read as definitive causal estimates, but they underscore the relevance of governance capacity for future pandemic preparedness.

PMID 42464377
Read full article →
PubMedmedRxiv : the preprint server for health sciences2026-07-17

Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus.

Butzin-Dozier Zachary Z, Wang Lin-Chiun LC, Ji Yunwen Y, Anzalone A Jerrod AJ et al.

Metformin is one of the most commonly prescribed medications for individuals with diabetes and may provide protection against long-term sequelae of COVID-19. We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with type 2 diabetes mellitus and COVID-19 who were prescribed metformin or a dipeptidyl peptidase-4 inhibitor (DPP4i) at least 30 days before the onset of acute COVID-19 between October 1, 2021, and November 15, 2023. We compared the 12-month cumulative incidence of Long COVID diagnosis (ICD-10 U09.9: Post COVID-19 condition, unspecified), probable Long COVID (based on a model-derived phenotype), and mortality between individuals prescribed metformin vs. DPP4i. We applied Super Learner and targeted maximum likelihood estimation to obtain risk ratios while adjusting for covariates of interest. In our sample of 53,332 individuals with type 2 diabetes and COVID-19, we found that metformin prescription was associated with a lower risk of all-cause mortality after COVID-19 (adjusted risk ratio [aRR] 0.61, 95% CI 0.51, 0.73). We also observed that metformin users, compared to DPP4i users, had a slightly lower risk of probable Long COVID (aRR 0.87, 95% CI 0.81, 0.94) but did not detect a significant relationship with Long COVID diagnosis (aRR 0.90, 95% CI 0.68, 1.20), although we observed similar point estimates across Long COVID outcomes. These findings support the hypothesis that metformin prescription during acute COVID-19 may be associated with lower mortality among adults with diabetes. These analyses also provide modest evidence of a protective association against Long COVID in adults with diabetes, although estimates were imprecise.

PMID 42465953
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about COVID-19 vaccine